source
- Tolerance Bio secures up to $260 M for thymus‑targeting fusion protein, moves into Phase 2 trialsTolerance Bio, a Philadelphia biotech founded in October 2024, has signed a licensing agreement to acquire rights to NeoImmuneTech’s long‑acting IL‑7 fusion protein, efineptakin alfa, for up to $26…
- Immunologist Liz Marnik, raised unvaccinated, now advocates for science and empathy in vaccine discussionsImmunologist Liz Marnik grew up in a household that rejected vaccines, and she herself went without any immunizations into adulthood. At age 23 she visited a travel clinic and received all standar…